NOTE: There are a lot on my watchlist today which did not yet run. Please do include them in your watchlist up to next week because there are delayed market reactions to news overshadowed by runners. $Chimerix (CMRX.US)$PR 12/9 after hours To Submit Dordaviprone For Accelerated Approval To U.S. FDA For Patients With Recurrent H3 K27M-Mutant Diffuse Glioma Before Year-End. Ran 100%+ but this is after hour news with conference call tomorrow at 8:30AM ET. May co...
Jaguar8
OP
michael_11
:
Yes mostly because it increases EPS, less dilution risk, and gives more value to shareholders and attractive to investors. Drawback is it has higher volatility and lesser liquidity
$Chimerix (CMRX.US)$ PR 12/9 after hours To Submit Dordaviprone For Accelerated Approval To U.S. FDA For Patients With Recurrent H3 K27M-Mutant Diffuse Glioma Before Year-End. Ran 100%+ but this is after hour news with conference call tomorrow at 8:30AM ET. May co...
On Watch for tomorrow, likely will be a target for shorts though, we'll see.
📊⚡️📊
No comment yet